Issue Date: June 12, 2017
Merck, F-star join for bispecific antibodies
In a bid to become a leader in immuno-oncology, Merck KGaA has sealed a broad pact with F-star, a privately held firm focused on developing bispecific antibodies. F-star could score up to $130 million in the first two years of the collaboration, which gives Merck an exclusive option to acquire five bispecific antibodies against immuno-oncology targets. The option includes F-star’s lead preclinical product, FS118, an antibody that inhibits PD-L1 and LAG3.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society